

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 1/16, 1/18, 1/22, 5/00</b>	<b>A1</b>	(11) International Publication Number: <b>WO 98/12208</b>
		(43) International Publication Date: 26 March 1998 (26.03.98)
(21) International Application Number: <b>PCT/US97/16937</b> (22) International Filing Date: 19 September 1997 (19.09.97)  (30) Priority Data: 08/717,239           20 September 1996 (20.09.96)   US Not furnished       19 September 1997 (19.09.97)   US  (71) Applicant: <b>THE UNIVERSITY OF NEW MEXICO [US/US];</b> Patent Administration Office, Hokona Hall, Room 357, Albuquerque, NM 87131 (US).  (72) Inventors: <b>WALLEN, Erik, S.; 3901 Montgomery, N.E. #308,</b> <b>Albuquerque, NM 87109 (US). ROIGAS, Jan; Papellallee</b> <b>36/37, D-10437 Berlin (DE). MOSELEY, Pope, L.; 9420</b> <b>Eagle Rock, N.E., Albuquerque, NM 87122 (US).</b>  (74) Agent: <b>JAGTIANI, Ajay, A.; Jagtiani &amp; Associates, 6126</b> <b>Rocky Way Court, Centreville, VA 20120-3400 (US).</b>		(81) Designated States: BR, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report.</i>
(54) Title: <b>HEAT SHOCK PROTEIN COMPLEXES</b>		
(57) Abstract  A method for purifying heat shock protein complexes is provided which comprises the steps of adding a solution containing heat shock protein complexes, in which heat shock proteins are associated with peptides, polypeptides, denatured proteins or antigens, to a column containing an ADP matrix to bind the heat shock protein complexes to the ADP matrix and adding a buffer containing ADP to the column to remove the heat shock protein complexes in an elution product. Additionally a method for synthesizing heat shock protein complexes and purifying the complexes so produced is provided which comprises the steps of adding heat shock proteins to an ADP matrix column to bind them to the matrix, adding a solution of peptides, polypeptides, denatured proteins or antigens to the column to bind them to the heat shock protein as heat shock protein complexes and adding a buffer containing ADP to the column to remove the complexes in an elution product.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## HEAT SHOCK PROTEIN COMPLEXES

### BACKGROUND OF THE INVENTION

5

#### Field of the Invention

The present invention relates generally to methods for purifying and synthesizing heat shock protein complexes.

10

#### Description of the Prior Art

Heat shock proteins (HSPs) are associated in cells with a broad spectrum of peptides, polypeptides, denatured proteins and antigens with which they form complexes. Such HSP-peptide complexes have been described as being useful in vaccines against cancers and infectious diseases by Srivastava *et al.*, "Heat shock protein-peptide complexes in cancer immunotherapy" in *Current Opinion in Immunology* (1994), 6:728-732; Srivastava, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum" in *Advances in Cancer Research* (1993), 62:153-177.

The HSP-peptide complexes appear to work as vaccines, because they may function as antigen carrying and presentation molecules. The development of vaccines using such antigens has been described by Baltz, "Vaccines in the treatment of Cancer" in *Am. J. Health-Syst. Pharm.* (1995), 52:2574-2585. The antigenicity of heat shock proteins appears to derive not from the heat shock protein itself, but from the associated peptides, see Udono *et al.*, "Heat Shock Protein 70-associated Peptides Elicit Specific Cancer Immunity" in *J. Exp. Med.* (1993), 178:1391-1396; Srivastava *et al.*, "Heat shock proteins transfer peptides during antigen processing and CTL priming" in *Immunogenetics* (1994), 39:93-98; Srivastava, "A Critical Contemplation on the Roles of Heat Shock Proteins in Transfer of Antigenic Peptides During Antigen Presentation" in *Behring Inst. Mitt.* (1994), 94:37-47. HSPs appear to be part of the process by which peptides are transported to the Major Histocompatibility Complex (MHC) molecules for surface presentation.

A number of different HSPs have been shown to exhibit immunogenicity including: gp96, hsp90 and hsp70, see Udono *et al.*, *supra.* and Udono *et al.*, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp 70" in *Journal of Immunology* (1994), 5398-5403; gp96 and grp94, Li *et al.*, "Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation" in *The EMBO Journal*, Vol. 12, No. 8 (1993), 3143-3151; and gp96, hsp90 and hsp70, Blachere *et al.*, "Heat Shock Protein Vaccines Against Cancer" in *Journal Of Immunotherapy* (1993), 14:352-356.

10

Heat shock proteins have been purified using a procedure employing DE52 ion-exchange chromatography followed by affinity chromatography on ATP-agarose, see Welch *et al.*, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides" in *Molecular and Cellular Biology* (June 1985), 1229-1237. However, previous methods of purifying HSPs such as this one purify the heat shock proteins without the associated peptides. Other methods that do purify HSPs together with their associated peptides are complicated and expensive.

20

#### SUMMARY OF THE INVENTION

Therefore, it is an object of the invention to provide a simple and inexpensive method for purifying heat shock proteins together with their associated peptides, polypeptides, denatured proteins or antigens from cell lysates.

25

It is a further object of the invention to provide a method for synthesizing heat shock protein complexes that is capable of forming these complexes from heat shock proteins and peptides, polypeptides, denatured proteins or antigens from different cells and from different species.

30

The present invention provides a method for purifying heat shock protein complexes comprising the steps of adding a solution containing heat shock protein complexes, in which heat shock proteins are associated with peptides, polypeptides, denatured proteins or antigens, to a column containing an ADP matrix to bind the heat shock proteins complexes to the ADP matrix and then adding a buffer containing ADP to the column remove the heat shock protein complexes in an elution product.

The present invention also provides a method for synthesizing heat shock protein complexes and purifying the complexes so produced by adding heat shock proteins to an ADP matrix column to bind them to the matrix, adding a solution of peptides, polypeptides, denatured proteins or antigens to the column to bind them to the heat shock proteins as heat shock protein complexes and then adding a buffer containing ADP to the column to remove the complexes in an elution product.

15

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a drawing of a western blot of fractions taken from a purification using the ADP purification matrix;

20

Figure 2 is a plot of HPLC data of material treated with NaCl after being purified by the method of the invention and filtered through a 20,000 molecular weight cut-off filter; and

25

Figure 3 is a plot of HPLC data of material treated with ATP after being purified by the method of the invention and filtered through a 20,000 molecular weight cut-off filter.

30

**DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

In one preferred embodiment, the present invention provides a method for isolating heat shock protein complexes from a solution containing heat shock proteins using an ADP matrix. Each of the heat shock protein complexes consists of a heat shock protein (HSP) that is bound tightly to an incomplete protein in a cell.

According to the method of the invention, solutions containing these HSP complexes are added to a conventional column, such as an agarose gel column, to which ADP has been added to form an ADP matrix. Suitable ADP-agarose columns include those described in U.S. Patent Nos. 5,114,852; 5,268,465; 5,132,407; and 5,541,095, the entire contents and disclosures of which are hereby incorporated by reference. ADP has a strong affinity for the HSP complexes and unlike ATP, does not break down the HSP complexes when it binds to them.

Typically the solution from which the heat shock protein complexes are purified is a cell lysate from a tumor in which the HSPs are already present. However, the invention contemplates that the solution containing HSP complexes to be purified may be produced by mixing an already purified heat shock protein with a cell lysate, a membrane isolate (materials isolated from a cell membrane) or a protease treated cell lysate containing peptides, polypeptides, denatured proteins to produce a solution of HSP complexes. For the purposes of the present invention the term "peptides" refers to all peptides and polypeptides including denatured proteins, and recombinant or otherwise purified tumor or infectious disease antigens that may be associated with heat shock proteins, either naturally or synthetically.

In order to increase the number of heat shock proteins in the solution added to the ADP matrix column, the solution may be incubated at a temperature of 37 to 50°C. and additional ADP may be added to the solution prior to adding it to the column. If the HSP complex solution is a cell lysate, additional HSPs may be added to the lysate to form additional complexes.

A buffer solution containing ADP is added to the column to elute the HSP complexes from the ADP matrix as an elution product containing the HSP complexes. In addition to ADP, this buffer solution may also contain small amounts of components such as sodium chloride that aid in the removal of the complexes from the ADP matrix.

In order to produce a more purified elution product, after the HSP complexes have been bound to the ADP matrix, a purifying buffer solution may be added to the column to elute other proteins loosely bound to the matrix. This purifying buffer solution preferably contains GTP or another non-adenosine containing nucleotide

The method of the invention takes advantage of the fact that HSPs are associated with peptides inside the cell. This purification method maintains the HSP-peptide association necessary to develop vaccines or immunotherapeutic tools for tumors and for infectious diseases since HSPs have not been shown to be helpful as antigens without the associated peptides.

In another embodiment the invention provides a method for synthesizing HSP complexes and purifying the complexes so produced. In this method, purified HSPs are bound to an ADP matrix column. Then a preparation of peptides, polypeptides, denatured proteins and/or antigens is added to an ADP matrix column to bind to the HSPs in the matrix. The method then proceeds similarly to the first embodiment of the invention. A buffer solution containing ADP is added to the column to elute the HSP complexes from the ADP matrix as an elution product containing the HSP complexes. This buffer solution may contain small amounts of components such as sodium chloride that aid in the removal of the complexes from the ADP matrix.

As with the first embodiment of the invention, a purifying buffer solution containing GTP or another non-adenosine containing nucleotide may be added to the column to elute other proteins loosely bound to the matrix.

This second embodiment permits HSP complexes to be formed from HSPs and peptides, denatured proteins or antigens from different cells or even different species.

5           Although there are many heat shock proteins that may be used in the method of the present invention, heat shock proteins that have proven particularly useful include members of the hsp60 family, hsp70 family, hsp90 family and the hsp104-105 family.

10           Members of the hsp60 family include hsp60, hsp65, rubisco binding protein, and TCP-1 in eukaryotes; and GroEl/GroES in prokaryotes; Mif4, and TCP1alpha and beta in yeast.

15           Members of the hsp70 family include DnaK proteins from prokaryotes, Ssa, Ssb, and Ssc from yeast, hsp70, Grp75 and Grp78(Bip) from eukaryotes. Figure 1 is a drawing of a western blot of fractions taken from a purification using the method of the invention. The elution was started at fraction #10 and hsp70 protein appears in fraction #14.

20           Members of the hsp90 family include hsp90, g96 and grp94.

Members of the hsp104-105 family include hsp105 and hsp110.

25           The HSP/peptide complexes are eluted from the matrix using an ADP containing buffer. It also helps HSPs to be added to peptide mixtures and the complexes for use as a vaccine.

30           The invention will now be described by way of example. The following examples are illustrative and are not meant to limit the scope of the invention which is set forth by the appointed claims.

## EXAMPLE 1

A confluent T-75 of B16-F1 mouse melanoma cells was rinsed 3x with PBS. 1 ml of PBS was added and the cells were scraped to create a suspension. The suspension was spun for 5 minutes at 1000rpm to pellet the cells. The supernatant was removed and the cells resuspended in 1.5 ml of a hypotonic buffer (30mM NaHCO<sub>3</sub>, pH 7.1). The suspension was transferred to a glass tube and the cells were lysed with a Teflon® pestle and power drill. The lysate was transferred to a microcentrifuge tube and spun at high speed to pellet the undissolved fraction. Total protein of the lysate was determined using the Bradford method. Solution containing 100µg of total protein was brought up to 300µl total volume with the addition of Phosphate buffer (0.1M KH<sub>2</sub>PO<sub>4</sub>, 10 mM NaCl, 1mM EDTA, pH 7.2) and the solution was added to a 5 ml ADP-agarose column (linked through C-8, Sigma Chemical Co.) and allowed to run into the column with 5 ml of Phosphate buffer and then buffer B (20mM TRIS, 20mM NaCl, 15 mM EDTA, 15mM Beta-mercaptoethanol, pH 7.5) with 60mM ADP was added at the start of fraction 10 to elute the complexes. After completion of the run, 50µl of each fraction was run onto a 7.5% SDS PAGE gel, transferred to nitrocellulose, probed with an antibody for the inducible and constitutive hsp70 (N27, Stressgen Biotechnologies), and then a secondary alkaline phosphate linked antibody. A blot was developed in a buffer containing BCIP and NBT. A drawing of this plot is shown in Figure 1.

## EXAMPLE 2

PC-3 lysate was run over a agarose column containing an ADP matrix according the method of the invention. The HSP containing fraction was then eluted  
5 with ADP. The eluted fraction containing HSPs was filtered using a 20,000 molecular weight cut-off (MWC) filter and several rinses of buffer A (25mMTris, 20mM Hepes, 47.5mM KCl, and 2.25mM Mg(OAc)<sub>2</sub>, pH 7.2) were applied. The sample was split into two microcentrifuge tubes and either ATP (to 10mM) or NaCl (to 1mM) was added. The tubes were then incubated overnight at 37°C. Each solution was then spun  
10 through a 20,000MWC filter and the filtered material was applied to an HPLC column. The HPLC was accomplished using a C18 reverse phase column (Vydac, 201TB54). The starting buffer was 0.1% TFA in dH<sub>2</sub>O and the material was eluted using a gradient of 0.1% TFA in ACN. Figure 2 shows HPLC data for the material treated with NaCl after being purified with the ADP matrix and filtered through the  
15 20,000 molecular weight cut-off filter. Figure 3 shows the HPLC data for the material treated with ATP after being purified with the ADP matrix and filtered through the 20,000 molecular weight cut-off filter. The HPLC data in Figures 2 and 3 is consistent with the data for hsp70 described in Udono *et al.*, "Heat Shock Protein 70-associated Peptides Elicit Specific Cancer Immunity" in *J. Exp. Med.* (1993), 178:1391-1396.

20

Although the present invention has been fully described in conjunction with the preferred embodiment thereof with reference to the accompanying drawings, it is to be understood that various changes and modifications may be apparent to those skilled in the art. Such changes and modifications are to be understood as included  
25 within the scope of the present invention as defined by the appended claims, unless they depart therefrom.

**WHAT IS CLAIMED**

1. A method for purifying heat shock protein complexes comprising the steps of:

adding a heat shock protein complex comprising a heat shock protein associated with at least one member of the group consisting of peptides, polypeptides, denatured proteins and antigens associated therewith to ADP matrix column containing an ADP matrix to bind the heat shock protein complexes to the ADP matrix; and

adding a buffer containing ADP to the column to remove the heat shock protein complexes in an elution product.

2. The method of claim 1 further comprising the step of adding a purifying buffer solution comprising at least one member of the group consisting of GTP and a non-adenosine containing nucleotides to the ADP matrix column to elute proteins that are loosely bound with the ADP matrix column.
3. The method of claim 1 wherein the solution containing heat shock protein complexes comprises a cell lysate.
4. The method of claim 1 further comprising the step of incubating the solution containing heat shock protein complexes at a temperature of 37 to 50°C. prior to adding the solution to the column to induce heat shock proteins present in the solution

to bind to peptides, polypeptides, denatured proteins and antigens present in the solution to form heat shock protein complexes.

5. The method of claim 1 further comprising the step of adding ADP to the solution containing heat shock protein complexes prior to adding the solution to the column to induce heat shock proteins present in the solution to bind to peptides, polypeptides, denatured proteins and antigens present in the solution to form heat shock protein complexes.
6. The method of claim 1 further comprising the step of adding a buffer solution containing GTP to the column to elute proteins other than heat shock proteins that are loosely bound to the matrix.
7. The method of claim 1 further comprising adding purified heat shock proteins to the solution containing heat shock proteins prior to adding the solution to the column.
8. The method of claim 1 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of hsp60, hsp65, rubisco binding protein and TCP-1 from eukaryotes; GroEL/GroES, Mif4, TCPalpha and TCPbeta from yeast.

9. The method of claim 1 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises of one of the group consisting of hsp104, hsp105 and hsp110.

10. The method of claim 1 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of DnaK proteins from prokaryotes; Ssa, Ssb, and Ssc from yeast; hsp70, Grp75 and Grp78(Bip) from eukaryotes.

11. The method of claim 1 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of hsp90, g96 and grp94.

12. The method of claim 1 further comprising the step of producing the heat shock protein complex by mixing a heat shock protein with a complexing agent selected from the group consisting of peptides, polypeptides, denatured proteins and antigens.

13. A method for synthesizing heat shock protein complexes comprising the steps of:

adding a heat shock protein to an ADP matrix column to bind the heat shock protein;

adding a complexing solution comprising a complexing agent selected from the group consisting of peptides, polypeptides, denatured proteins and antigens to the column to form a heat shock protein complex with the heat shock protein bound to the ADP matrix column; and

adding a buffer containing ADP to the column to remove the heat shock protein complex in an elution product.

14. The method of claim 13 further comprising the step of adding a purifying buffer solution comprising at least one of the group consisting of GTP and a non-adenosine containing nucleotide to the column to elute proteins that are loosely bound with the ADP matrix column.

15. The method of claim 13 wherein the complexing solution comprises a peptide mixture selected from the group consisting of cell lysates, membrane isolates, and protease treated cell lysates.

16. The method of claim 13 further comprising the step of incubating the solution containing heat shock protein complexes at a temperature of 37 to 50°C. prior to adding the solution to the column to induce heat shock proteins present in the solution to bind to peptides, polypeptides, denatured proteins and antigens present in the solution to form heat shock protein complexes.

17. The method of claim 13 further comprising the step of adding ADP to the solution containing heat shock protein complexes prior to adding the solution to the column to induce heat shock proteins present in the solution to bind to peptides, polypeptides, denatured proteins and antigens present in the solution to form heat shock protein complexes.

18. The method of claim 13 further comprising the step of adding a buffer solution containing GTP to the column to elute proteins other than heat shock proteins that are loosely bound to the matrix.

19. The method of claim 13 further comprising adding purified heat shock proteins to the solution containing heat shock proteins prior to adding the solution to the column.

20. The method of claim 13 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of hsp60, hsp65, rubisco binding protein and TCP-1 from eukaryotes; GroEL/GroES, Mif4, TCPalpha and TCPbeta from yeast.

21. The method of claim 13 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of hsp104, hsp105 and hsp110.

22. The method of claim 13 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of DnaK proteins from prokaryotes; Ssa, Ssb, and Ssc from yeast; hsp70, Grp75 and Grp78(Bip) from eukaryotes.

23. The method of claim 13 wherein the heat shock protein complexes include complexes in which the heat shock protein comprises one of the group consisting of hsp90, g96 and grp94.
24. An ADP-heat shock protein-peptide complex in substantially purified form.
25. The ADP-heat shock protein-peptide complex of claim 24, wherein said heat shock protein comprises one of the group consisting of hsp60, hsp65, rubisco binding protein and TCP-1 from eukaryotes; GroEL/GroES, Mif4, TCPalpha and TCPbeta from yeast.
26. The ADP-heat shock protein-peptide complex of claim 24, wherein said heat shock protein comprises one of the group consisting of hsp104, hsp105 and hsp110.
27. The ADP-heat shock protein-peptide complex of claim 24, wherein said heat shock protein comprises one of the group consisting of DnaK proteins from prokaryotes; Ssa, Ssb, and Ssc from yeast; hsp70, Grp75 and Grp78(Bip) from eukaryotes.
28. The ADP-heat shock protein-peptide complex of claim 24, wherein said heat shock protein comprises one of the group consisting of hsp90, g96 and grp94.
29. The ADP-heat shock protein-peptide complex of claim 24, wherein said peptide comprises one of the group consisting of polypeptides and proteins.

30. The ADP-heat shock protein-peptide complex of claim 24, wherein said ADP-heat shock protein-peptide complex comprises a synthetic heat shock protein-peptide complex.

31. The ADP-heat shock protein-peptide complex of claim 30, wherein said synthetic heat shock protein-peptide complex comprises a heat shock protein from one cell and a peptide from a second cell of the same individual.

32. The ADP-heat shock protein-peptide complex of claim 30, wherein said synthetic heat shock protein-peptide complex comprises a heat shock protein from one individual and a peptide from a second individual.

33. The ADP-heat shock protein-peptide complex of claim 30, wherein said synthetic heat shock protein-peptide complex comprises a heat shock protein from one organism and a peptide from a second organism.

34. The ADP-heat shock protein-peptide complex of claim 30, wherein said synthetic heat shock protein-peptide complex comprises a heat shock protein from one species and a peptide from a second species.

35. The ADP-heat shock protein-peptide complex of claim 24, wherein the ADP-heat shock protein-peptide complex is purified by the steps of:

adding a heat shock protein complex comprising a heat shock protein associated with at least one member of the group consisting of peptides, polypeptides, denatured proteins and antigens associated therewith to ADP matrix column containing an ADP matrix to bind the heat shock protein complexes to the ADP matrix; and

adding a buffer containing ADP to the column to remove the heat shock protein complexes in an elution product.

36. The ADP-heat shock protein-peptide complex of claim 24, wherein said ADP-heat shock protein-peptide complex is synthesized by the steps of:

adding a heat shock protein to an ADP matrix column to bind the heat shock protein;

adding a complexing solution comprising a complexing agent selected from the group consisting of peptides, polypeptides, denatured proteins and antigens to the column to form a heat shock protein complex with the heat shock protein bound to the ADP matrix column; and

adding a buffer containing ADP to the column to remove the heat shock protein complex in an elution product.




Figure 1

FIGURE 2  
 A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V. W. X. Y. Z. AA. AB. AC. AD. AE. AF. AG. AH. AI. AJ. AK. AL. AM. AN. AO. AP. AQ. AR. AS. AT. AU. AV. AW. AX. AY. AZ. BA. BB. BC. BD. BE. BF. BG. BH. BI. BJ. BK. BL. BM. BN. BO. BP. BQ. BR. BS. BT. BU. BV. BW. BX. BY. BZ. CA. CB. CC. CD. CE. CF. CG. CH. CI. CJ. CK. CL. CM. CN. CO. CP. CQ. CR. CS. CT. CU. CV. CW. CX. CY. CZ. DA. DB. DC. DD. DE. DF. DG. DH. DI. DJ. DK. DL. DM. DN. DO. DP. DQ. DR. DS. DT. DU. DV. DW. DX. DY. DZ. EA. EB. EC. ED. EE. EF. EG. EH. EI. EJ. EK. EL. EM. EN. EO. EP. EQ. ER. ES. ET. EU. EV. EW. EX. EY. EZ. FA. FB. FC. FD. FE. FF. FG. FH. FI. FJ. FK. FL. FM. FN. FO. FP. FQ. FR. FS. FT. FU. FV. FW. FX. FY. FZ. GA. GB. GC. GD. GE. GF. GG. GH. GI. GJ. GK. GL. GM. GN. GO. GP. GQ. GR. GS. GT. GU. GV. GW. GX. GY. GZ. HA. HB. HC. HD. HE. HF. HG. HH. HI. HJ. HK. HL. HM. HN. HO. HP. HQ. HR. HS. HT. HU. HV. HW. HX. HY. HZ. IA. IB. IC. ID. IE. IF. IG. IH. II. IJ. IK. IL. IM. IN. IO. IP. IQ. IR. IS. IT. IU. IV. IW. IX. IY. IZ. JA. JB. JC. JD. JE. JF. JG. JH. JI. JJ. JK. JL. JM. JN. JO. JP. JQ. JR. JS. JT. JU. JV. JW. JX. JY. JZ. KA. KB. KC. KD. KE. KF. KG. KH. KI. KJ. KK. KL. KM. KN. KO. KP. KQ. KR. KS. KT. KU. KV. KW. KX. KY. KZ. LA. LB. LC. LD. LE. LF. LG. LH. LI. LJ. LK. LL. LM. LN. LO. LP. LQ. LR. LS. LT. LU. LV. LW. LX. LY. LZ. MA. MB. MC. MD. ME. MF. MG. MH. MI. MJ. MK. ML. MM. MN. MO. MP. MQ. MR. MS. MT. MU. MV. MW. MX. MY. MZ. NA. NB. NC. ND. NE. NF. NG. NH. NI. NJ. NK. NL. NM. NN. NO. NP. NQ. NR. NS. NT. NU. NV. NW. NX. NY. NZ. OA. OB. OC. OD. OE. OF. OG. OH. OI. OJ. OK. OL. OM. ON. OO. OP. OQ. OR. OS. OT. OU. OV. OW. OX. OY. OZ. PA. PB. PC. PD. PE. PF. PG. PH. PI. PJ. PK. PL. PM. PN. PO. PP. PQ. PR. PS. PT. PU. PV. PW. PX. PY. PZ. QA. QB. QC. QD. QE. QF. QG. QH. QI. QJ. QK. QL. QM. QN. QO. QP. QQ. QR. QS. QT. QU. QV. QW. QX. QY. QZ. RA. RB. RC. RD. RE. RF. RG. RH. RI. RJ. RK. RL. RM. RN. RO. RP. RQ. RR. RS. RT. RU. RV. RW. RX. RY. RZ. SA. SB. SC. SD. SE. SF. SG. SH. SI. SJ. SK. SL. SM. SN. SO. SP. SQ. SR. SS. ST. SU. SV. SW. SX. SY. SZ. TA. TB. TC. TD. TE. TF. TG. TH. TI. TJ. TK. TL. TM. TN. TO. TP. TQ. TR. TS. TT. TU. TV. TW. TX. TY. TZ. UA. UB. UC. UD. UE. UF. UG. UH. UI. UJ. UK. UL. UM. UN. UO. UP. UQ. UR. US. UT. UU. UV. UW. UX. UY. UZ. VA. VB. VC. VD. VE. VF. VG. VH. VI. VJ. VK. VL. VM. VN. VO. VP. VQ. VR. VS. VT. VU. VV. VW. VX. VY. VZ. WA. WB. WC. WD. WE. WF. WG. WH. WI. WJ. WK. WL. WM. WN. WO. WP. WQ. WR. WS. WT. WU. WV. WW. WX. WY. WZ. XA. XB. XC. XD. XE. XF. XG. XH. XI. XJ. XK. XL. XM. XN. XO. XP. XQ. XR. XS. XT. XU. XV. XW. XX. XY. XZ. YA. YB. YC. YD. YE. YF. YG. YH. YI. YJ. YK. YL. YM. YN. YO. YP. YQ. YR. YS. YT. YU. YV. YW. YX. YY. YZ. ZA. ZB. ZC. ZD. ZE. ZF. ZG. ZH. ZI. ZJ. ZK. ZL. ZM. ZN. ZO. ZP. ZQ. ZR. ZS. ZT. ZU. ZV. ZW. ZX. ZY. ZZ.

2.448  
 4.758

20.478  
 26.483

30.133  
 31.447  
 32.743

39.444  
 38.478  
 37.133  
 37.948


40.701  
 42.202  
 42.943  
 43.883  
 43.144  
 43.914

40.444  
 47.147  
 50.244  
 51.444

54.144  
 TIME/SCALE STEP

XXXXXXXXXX BMP

Figure 3



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/16937

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 1/16, 1/18, 1/22, 5/00

US CL : 530/350, 412, 416, 417

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 412, 416, 417

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS, DIALOG (MEDLINE, EMBASE, BIOSIS)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MINAMI et al. Regulation of the Heat-shock Protein 70 Reaction Cycle by the Mammalian DnaJ Homolog, HSP40. The Journal of Biological Chemistry. 09 August 1996. Vol. 271. No. 32. pages 19617-19624, see entire document.	1-36
A	GREENE et al. Effect of Nucleotide on the Binding of Peptides to 70-kDa Heat Shock Protein. The Journal of Biological Chemistry. 17 February 1995. Vol 270. No. 7. pages 2967-2973, see entire document.	1-36
A	HA et al. ATPase Kinetics of Recombinant Bovine 70 kDa Heat Shock Cognate Protein and Its Amino-Terminal ATPase Domain. Biochemistry. 1994. Vol 33. pages 14625-14635, see entire document.	1-36

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 NOVEMBER 1997

Date of mailing of the international search report

12 DEC 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
JOHN BUEAS

Telephone No. (703) 308-0196

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 39/002, 39/02, 39/118, 39/12, 39/295, C07K 17/00</b>		A3	(11) International Publication Number: <b>WO 95/24923</b>
			(43) International Publication Date: 21 September 1995 (21.09.95)
(21) International Application Number: PCT/US95/03311		(74) Agent: MISROCK, S. Leslie; Pennie & Edmonds, 1155 Ave. of the Americas, New York, NY 10036 (US).	
(22) International Filing Date: 16 March 1995 (16.03.95)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 210,421 16 March 1994 (16.03.94) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(60) Parent Application or Grant (63) Related by Continuation US 08/210,421 (CIP) Filed on 16 March 1994 (16.03.94)		(88) Date of publication of the international search report: 12 October 1995 (12.10.95)	
(71) Applicant (for all designated States except US): MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK [US/US]; One Gustave L. Levy Place, New York, NY 10029 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SRIVASTAVA, Pramod, K. [IN/US]; Apartment 3E, 27 East 49th Street, New York, NY 10128 (US). UDONO, Heiichiro [JP/JP]; 1-2-RF303 Tsushima-Naka, Okayama 700 (JP). BLACHERE, Nathalie, E. [US/US]; Apartment 18D, 510 East 86th Street, New York, NY 10028 (US).			
(54) Title: STRESS PROTEIN-PEPTIDE COMPLEXES AS PROPHYLACTIC AND THERAPEUTIC VACCINES AGAINST INTRA-CELLULAR PATHOGENS			
(57) Abstract <p>Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative to initiate in the mammal a cytotoxic T cell response against cells infected with a preselected intracellular pathogen. Also disclosed are methodologies for preparing and administering vaccines containing such stress protein-peptide complexes.</p>			

# INTERNATIONAL SEARCH REPORT

Int. onal Application No  
PCT/US 95/03311

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K39/002 A61K39/02 A61K39/118 A61K39/12 A61K39/295  
C07K17/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EUR. J. IMMUNOL., vol. 22, 1992 pages 1365-1372, C. BARRIOS ET AL. 'Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming.' see page 1365, paragraph 1 - page 1366 see page 1366, paragraph 2.2 see page 1370, paragraph 4	1-3, 11, 12, 17
Y	Discussion, first and second paragraphs --- -/--	4-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

6

Date of the actual completion of the international search

14 July 1995

Date of mailing of the international search report

29.08.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Halle, F

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/03311

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	CHEMICAL ABSTRACTS, vol. 121, no. 23, 5 December 1994 Columbus, Ohio, US; abstract no. 271089a, SRIVASTAVA P.K. AND UDONO H. 'Heat-shock protein-peptide complexes in cancer immunotherapy.' page 12;	1-3
Y	see abstract & CURR. OPIN. IMMUNOL., vol. 6, no. 5, 1994 pages 728-732,	4-36
X,P	WO-A-94 29459 (WHITEHEAD BIOMEDICAL INST) 22 December 1994 see the whole document	1-3
Y	WO-A-94 03208 (YEDA RES & DEV ;COHEN IRUN R (IL); FRIDKIN MATITYAHU (IL); KONEN W) 17 February 1994 see page 7, line 17 - page 8, line 32 see claims 1-5,20-25	4-36
A	WO-A-93 18146 (INST NAT SANTE RECH MED) 16 September 1993 see the whole document	1-3
A	EXPERIENTIA, vol. 50, 1994 pages 1054-1060, P. K. SRIVASTAVA 'Heat shock proteins in immune response to cancer: The Fourth Paradigm.'	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/03311

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-30  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 18-30 are directed to a method of treatment of the human or animal body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter nal Application No  
PCT/US 95/03311

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9429459	22-12-94	NONE	
WO-A-9403208	17-02-94	AU-B- 4790093	03-03-94
		CA-A- 2141454	17-02-94
		EP-A- 0658120	21-06-95
		FI-A- 950405	30-03-95
		NO-A- 950328	23-03-95
WO-A-9318146	16-09-93	FR-A- 2688227	10-09-93